[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$aard
Aardvark Therapeutics is advancing its Phase X trial for Prader-Willi Syndrome, with recent news of patient enrollment and dosing in Australia. Analysts maintain positive ratings, with some reiterating Buy recommendations and target prices.
About $aard
Aardvark Therapeutics is a biotechnology company focused on developing novel therapeutics for obesity and related disorders.
Insights
- $aard sentiment is up XXXXX% from the previous week.
Engagements: XXXXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXX
X Week: XXXXX -XX%
X Month: XXXXXX +12%
X Months: XXXXXXXXX +1,037%
1-Year High: XXXXXXX on 2025-07-17
1-Year Low: X on 2025-05-11
Engagements by network (24h): X: XXXXX
Mentions: XX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
X Week: XX -XX%
X Month: XXX +2.20%
X Months: XXXXXX +9,523%
1-Year High: XXXXX on 2025-07-18
1-Year Low: X on 2025-01-27
Mentions by network (24h): X: XXX
Creators: XX (24h)
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning $aard in the last XX hours which is up XX% from XX in the previous XX hours
Daily Average: XX
X Week: XX -XX%
X Month: XXX +29%
X Months: XXXXX +12,066%
1-Year High: XXXXX on 2025-07-18
1-Year Low: X on 2025-01-27
The most influential creators that mention $aard in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Quantumup1 | X | XXXXX | X | XXXXX |
| @CHItraders | X | XXXXX | X | XXX |
| @MarketCap_Live | X | XXX | X | XX |
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XXX% +12%
X Month: XX% no change
X Months: XX% -XX%
1-Year High: XXX% on 2025-01-23
1-Year Low: X% on 2025-10-07
Most Supportive Themes:
- Positive Mentions and Engagements: (20%) An increase in positive social media mentions and user engagements indicates growing interest and support for the company's initiatives.
- CEO Stock Purchases: (10%) CEO purchases of company stock signal strong confidence in the company's future prospects and financial health.
Most Critical Themes:
- Analyst Target Price Cut: (15%) A reduction in the target price by an analyst suggests a more cautious outlook on the stock's future performance.
Top $aard Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"INITIATIONS $AARD Outperform at William Blair $ASTH Buy at Needham; PT $XX $BMI Buy at Jefferies; PT $XXX $BA Buy at Citi; PT $XXX $BAH Neutral at Citi; PT $XX $CACI Neutral at Citi; PT $XXX $CELC Overweight at Wells Fargo; PT $XXX $GLW Buy at William O'Neil $CW Neutral at Citi; PT $XXX $DCO Buy at Citi; PT $XXX $GD Neutral at Citi; PT $XXX $GE Buy at Citi; PT $XXX $G Neutral at Susquehanna; PT $XX $GTE Buy at Roth; PT $XXXX $HEI Buy at Citi; PT $XXX $HWM Buy at Citi; PT $XXX $HII Buy at Citi; PT $XXX $KRMN Buy at Citi; PT $XX $LHX Buy at Citi; PT $XXX $LDOS Buy at Citi; PT $XXX $LOAR Buy at"
X Link @CHItraders 2025-12-12T13:55Z 5141 followers, XXX engagements
"+Initiations 12/12: $AARD $ALGT $APPF $ASTH $BMI $BTI $CELC $DAL $ENIC $GTE $HEI $HII $HWM $LIF $LOAR $NGG $NMG $PHAT $PL $PRCT $PSN $PTN $QXO $RAL $SAIC $SSB $TYL $UAL $VSEC $ZWS . -Initiations 12/12:"
X Link @OpenOutcrier 2025-12-12T13:41Z 79.9K followers, 1491 engagements
"BofA $RYTM's PT to $XXX from $XXX reiterated at a Buy rating and said 'Encouraging Early BMI and Hyperphagia Reduction SignalModel Changes' $SLNO $AARD Morgan StanleyPT to $XXX from $XXX reit'd at Buy/said Preliminary Ph2 setmelanotide data in PWS indicate promising and consistent signs of activity (BMI and hyperphagia) despite a challenging population supporting advancement into Ph3. We view early data as encouraging indicating potential to expansion into another blockbuster opportunity. Here's what else BofA had to say:"
X Link @Quantumup1 2025-12-11T18:28Z 3929 followers, 1970 engagements
"Raymond James reiterated $AARD Strong Buy/$47 $RYTM $SLNO Raymond James saidRemain Strong Buy rated on AARD shares following Rhythm's (RYTM not covered) presentation of preliminary Phase X data for setmelanotide in PWS. Recall this drug's mechanism differs from ARD-101 and it appears the drug's clinical utility differs as well. As we highlight herein setmelanotide appears to impact BMI more that hyperphagia and given the complexity of this disease we think combination therapy is likely where standard of care is headed. Given this we think ARD-101's value proposition as potentially"
X Link @Quantumup1 2025-12-11T17:29Z 3929 followers, 1875 engagements